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Anti-vascular endothelial growth factor (anti-VEGF) therapy applied to solid tumors is a promising strat-
egy, yet, the challenge to deliver these agents at high drug concentrations together with the maintenance
of therapeutic doses locally, at the tumor site, minimizes its benefits. To overcome these obstacles, we
propose the development of a bevacizumab-loaded alginate hydrogel by electrostatic interactions to
design a delivery system for controlled and anti-angiogenic therapy under tumor microenvironmental
conditions. The tridimensional hydrogel structure produced provides drug stability and a system able
to be introduced as a flowable solution, stablishing a depot after local administration. Biological perfor-
mance by the chick embryo chorioallantoic membrane (CAM) assay indicated a pH-independent
improved anti-angiogenic activity (50%) compared to commercial available anti-VEGF drug.
Moreover, there was a considerable regression in tumor size when treated with this system.
Immunohistochemistry highlighted a reduced number and disorganization of microscopic blood vessels
resulting from applied therapy. These results suggest that the developed hydrogel is a promising
approach to create an innovative delivery system that offers the possibility to treat different solid tumors
by intratumoral administration.
 2017 Elsevier B.V. All rights reserved.1. Introduction
Cancer is one of the most aggressive diseases leading to death
worldwide [1]. Despite all scientific knowledge and advances in
therapeutic discovery, the inability of drugs to reach the target site
of action by systemic delivery appears to be the major drawback
needing a denouement [2]. High doses of therapeutic agents lead
to unwanted side effects or toxicity in addition to compromising
patients’ quality of life [3]. Notwithstanding, a great attentionhas been given towards the development of delivery systems, use-
ful to provide sufficient quantities of drug at the target tissues,
besides extended or controlled release of these pharmaceutical
agents [2,4–6].
Anti-VEGF therapy based on the monoclonal antibody (mAb)
bevacizumab (BVZ) is a promising strategy for solid tumor treat-
ment since cancer initiation, growth and progression requires the
occurrence of angiogenesis, what ensures a nutritional and respira-
tory cell support [7–11]. However, clinical trials failed to demon-
strate encouraging results and, therefore, few FDA approved
protocols were established on its use alone or associated with
chemotherapeutic agents [12]. On the other hand, the use of BVZ
therapy for macular degeneration and diabetic retinopathy, has
received attention [13–16]. The spectrum of ocular diseases trea-
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ment when locally administered by intravitreal injections, in an
attempt to reach deeper eye areas [14]. Although its use appears
to avoid adverse side effects associated to systemic administration,
successful treatment requires high frequency of injections due the
limited drug half-life in the vitreous [2]. To overcome this limita-
tion, a series of implantable or injectable BVZ delivery systems
have been developed ensuring the increased concentration gradi-
ent, improving drug effect [2,17–19].
Whilst the extended serum half-life of BVZ [13] seems to sup-
port the limited attention focused on delivery systems applied to
anti-VEGF cancer therapy, other issues should be accounted for
[20]. As a protein macromolecule, BVZ exhibits a complex three-
dimensional structure hindering its permeation through biological
membranes [21]. Moreover, they display physicochemical instabil-
ity and susceptibility to environmental factors, conditions that
might be outlined by local delivery system technology through
intratumoral injections [21,22]. Besides, localized therapy applied
to cancer became particularly attractive when tumor cells are
accumulated in accessible body compartments [22–24].
The development of effective systems applied locally to cancer
therapy must consider the heterogeneity between tumor and nor-
mal tissue. Parts of tumor tissue are frequently hypoxic, resulting
in high glycolysis rates, required for energetic cell supply. Conse-
quently, the production of lactic acid results in an acid microenvi-
ronment [25–27]. A broad range of pH values are reported for
malignant tissues, however, variations are comprised, mostly,
between 5.8 and 7.4 [25,28,29].
Among all matrices used to delivery anticancer drugs directly to
tumor site, hydrogels stand as suitable candidates [30–34]. Their
high biocompatibility, reflected by their capacity to absorb large
amounts of biological fluids, renders a similarity to natural extra-
cellular matrix, mechanically and compositionally. Besides that,
the tridimensional porous structure, features a distinctive drug
delivery profile, which can be controlled by drug-matrix associa-
tions, drug diffusion though the network and system degradation
[35]. A series of biocompatible polymeric materials have already
been described for hydrogel development [30,33,36,37], among
them, alginate polysaccharide has remarkable interest as biomate-
rial and tissue engineering [38,39].
Alginate polymer has a peculiar gelling property under physio-
logical conditions, holding a good stability over a wide pH range, in
addition to being a polyelectrolyte surrounded by negative
charges, which offers the possibility of supramolecular association
with positively charged BVZ molecule [40,41].
Attempting to rescue the use of BVZ as anti-VEGF therapy in
cancer and, inspired by biologic systems and tumor microenviron-
ment characteristics, herein, we exploited calcium alginate hydro-
gels and the BVZ interaction to design anti-angiogenic delivery
systems for localized therapy [26]. To achieve this goal, the influ-
ence of alginate polymer on bevacizumab thermal and conforma-
tional stability was firstly evaluated under physiological (pH 7.4)
and tumor hypoxic microenvironmental conditions (pH 5.8 –
extreme reported value). The hydrogel was produced by mixing
alginate solution with the anti-VEGF agent bevacizumab, followed
by a subsequent crosslinking process within calcium chloride.
Detailed characterization of the physicochemical properties was
conducted. The anti-angiogenic and anti-neoplastic potential of
the developed hydrogel_BVZ was assessed by the in vivo chicken
chorioallantoic membrane (CAM) model. Our study provides a
proof of concept that BVZ loaded calcium alginate hydrogel is
effective as a release platform for the resumption of anti-VEGF
local cancer therapy, in addition to promote an improved drug
anti-angiogenic and anti-neoplastic activity independent on the
pH encountered in the tumors.2. Experimental section
2.1. Materials
Medium viscosity alginate sodium salt, derived from brown
algae, was purchased from Sigma-Aldrich (United Kingdom). Poly-
mer molecular weight was 107 ± 3.42 kDa, as measured by Static
light scattering. The polymer mannuronic/guluronic (M/G) ratio
was 1.93 determined by 1H NMR, according to Grasdalen [42,43].
Calcium Chloride (CaCl2) was purchased from Vetec. Avastin
(Bevacizumab injection 25 mg/mL, Roche Pharma Ltd., Switzer-
land) was purchased from Genentech. All other chemicals includ-
ing sodium chloride, lactic acid, dibasic sodium phosphate,
hydrochloric acid, sodium hydroxide were analytic reagent grades,
purchased from Sigma-Aldrich (São Paulo, Brazil). Dulbecco’s Mod-
ified Eagle Medium Gibco and all materials used for cell supply
were purchased from Invitrogen. Milli-Q grade water (Millipore)
was used for hydrogel preparation.
2.2. Methods
2.2.1. Effect of pH and polyanion alginate on bevacizumab
conformational and thermal stability
2.2.1.1. Circular dichroism (CD). Changes in secondary structure of
bevacizumab were evaluated in the presence of alginate polymer
using a Jasco J-815 spectropolarimeter coupled to a Peltier-type
temperature control system PFD 425S. BZV CD spectra were mea-
sured in 0.1 mm quartz cuvette containing polymer/protein (1:9 –
0.05/0.45 mg.mL1 and 5:5 – 0.25/0.25 mg.mL1) concentration in
50 mM phosphate-acetate buffer (pH 5.8 or 7.4) and compared
with freshly prepared bevacizumab (0.3 mg.mL1). Blank solutions
containing polymer at the same concentrations were measured to
subtract polymer contributions from the resultant CD spectra.
Spectra were collected at a 100 nm/min scan rate with of 0.5 nm
data pitch and normalized to mean residue molar ellipticity ([h]).
Protein secondary structure content was estimated using the
CDNN Deconvolution program [44].
2.2.1.2. Fluorescence spectroscopy. Protein local tertiary structure
and stability were analyzed by intrinsic fluorescence emission
experiments using F-4500 Hitachi fluorescence spectrophotometer
and 10  2 mm path length quartz cuvettes. Samples, composed of
0.5 mg.mL1 alginate/bevacizumab at three different polymer/pro-
tein ratios (1:9, 5:5 and 9:1) were excited at 280 nm and emission
spectra were collected from 300 to 420 nm. All measurements
were performed in 50 mM phosphate-acetate buffer (pH 5.8 or
7.4) and compared with freshly prepared bevacizumab (0.3 mg.
mL1). A blank solution containing the same polymer concentra-
tion was used as reference. Intrinsic fluorescence emission data
were analyzed using the maximum emission wavelength (kmax)
and the center of spectral mass (<k>), described by Eq. (1).
hki ¼
P
Fiki
P
Fi
ð1Þ
Where Fi is the fluorescence intensity at each ki wavelength.
2.2.1.3. Differential Scanning Microcalorimetry (Nano-DSC). DSC
measurements were made using a TA Instruments Nano-DSC.
Thermal denaturation scans were conducted from 0 to 100 C at
a rate of 1 C.min1. Acquired data shows thermal profile of freshly
prepared BVZ and BVZ against the presence of alginate polymer in
phosphate-acetate buffer pH 5.8 and 7.4. The reference cell was
filled with buffer solution and buffer solution containing alginate.
Thermodynamic parameters related to protein unfolding were
extracted from thermograms using Nano Analyze software.
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was first dispersed ‘‘overnight” (27 mg/mL) in purified water using
magnetic stirring at room temperature. pH was adjusted by the use
of hydrochloric acid (pH 5.8) and sodium hydroxide (pH 7.4) solu-
tions. For hydrogel preparation, a co-injection systemwith alginate
solution (10 mL) and the same amount of calcium chloride (5 mg/
mL) as crosslink agent was used [45]. The co-injection system was
based in the homogeneous addition of the polymer and crosslink-
ing solution, dropwise, under mechanical stirring. The pH was con-
trolled, and a maximal pH-deviation of ± 0.1 was allowed. For
systems containing BVZ protein (referred as hydrogel_BVZ), beva-
cizumab (3 mg/mL) was added before the crosslinking process in
polymer solution. In order to complete the process, hydrogels were
left under magnetic stirring for 30 min after preparation.
2.2.1.5. Zeta potential measurements. Samples were prepared as
already mentioned and placed in a plastic cuvette. Zeta potential
(ZP) of hydrogel at pH 7.4 and hydrogel_BVZ at pH 7.4 and 5.8
was determined by electrophoretic mobility using a Malvern
Instruments Zetasizer Nano ZS (United Kingdom) to analyze the
self-assembly process. Samples were diluted in ultra-purified
water. All data were obtained using the Helmholtz-
Smoluchowski approximation.
2.2.1.6. Syringeability test. Syringeability expresses the force
required for system injection at a given injection rate via a syringe
attached to a needle of predetermined gauge and length [46]. The
work required to extrude hydrogels produced with different con-
centrations of calcium chloride (3 mg/mL and 5 mg/mL), hydro-
gel_BVZ and commercial BVZ were determined using the TA-
XTplus Texture Analyzer (Stable Micro Systems) in compression
mode, by measuring the area under the resultant force [47–49].
Briefly, hydrogels were carefully packed into identical 3 mL plastic
syringes (BD PlastipakTM) coupled to 0.70  30 mm needle (BD Pre-
cision GlideTM), avoiding the introduction of air bubbles, ensuring
30 mm of formulation. The syringe was then vertically placed
under the probe, which was lowered up to the initial contact with
the plunger. To determine the work done, the probe was lowered
at constant speed (2 mm.s1 through a distance of 30 mm).
Increased work of syringeability was related to increased areas
under the curves. All measurements were performed at 25 C
and, at least in six replicates.
2.2.1.7. Hydrogel liquid uptake. Evaluation of hydrogel liquid uptake
capacity was performed by using an Enslin device [50,51] at both
5.8 and 7.4 pH values (phosphate-acetate buffer 50 Mm). For the
assay, 3 mg ± 0.5 of lyophilized hydrogel and hydrogel_BVZ sam-
ples were placed on the sintering filter. The volume of the media
was measured with a graduated pipette, coupled to the system.
Experiments were carried out in triplicate and results expressed
as sorption volume (S%) after 15, 30, 60, 120, 150 and 180 min
according to Eq. (2).
S% ¼ V
m
 100 ð2Þ
where S% is the percentage of sorption volume; V is volume (mL) of
media absorbed and m, initial mass of hydrogels.
2.2.1.8. Rheological behavior. Continuous flow and viscoelastic
properties of hydrogel and hydrogel_BVZ (pH 7.4) were analyzed
on a TA Instruments AR2000ex rheometer equipped with
parallel-plate geometry of 40 mm diameter, angle 2 and gap
61 lm. A total of 1.2 mL samples were carefully deposited onto
the lower base and equilibrated for 5 min before starting the mea-
surements. The flow test was performed using a controlled shearrate procedure in the range of 1–400 s1 and back, each stage last-
ing 180 s.
Oscillatory rheology measurements were fulfilled within the
linear viscoelastic region, applying 0.01–100 Hz frequency sweep
at a constant stress (0.5 Pa) to record storage modulus (G0) and loss
modulus (G00), which can provide useful information about the gel
structure [51,52]. Exponent n was obtained by fitting G0 as a func-
tion of frequency (x) into the power law equation (Eq. (3)) [41,53],
given by:
G0 ¼ S:xn ð3Þ
where G
0
is the storage modulus; S the gel strength; x the oscilla-
tion frequency and n is the viscoelastic exponent.
The temperature was maintained at 25 ± 0.1 C during all mea-
surements. In order to mimic system behavior at the acidic tumor
microenvironment, hydrogel and hydrogel_BVZ were additionally
analyzed against the presence of lactic acid (pH 5.8). All reported
values are the average of triplicate determinations.
2.2.1.9. Scanning electron microscopy. Field emission scanning elec-
tron microscopy (FEG-SEM) was performed on hydrogel and
hydrogel_BVZ to analyze gel porosity and morphology. Hydrogels
were instantly frozen by using liquid nitrogen and lyophilized for
48 h. A cross section of hydrogel sample was mounted with carbon
tape and coated with gold. Samples were imaged using a JOEL-JSM-
7500 F coupled to Joel Pc-100 ver. 2.1.0.3. Software.
2.3. Biological performance
2.3.1. Cells and cell culture
A glioma cell line (U251) was used for these studies as a model
of tumor cells, it was provided by Professor Joseph Costello, Califor-
nia University, Neurosurgery department, San Francisco. Authenti-
cation was performed at IdentiCell Laboratories (Department of
Molecular Medicine at Aarhus University Hospital Skejby, Arhus,
Denmark). The cell line was maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM 1, High Glucose; Gibco, Invitrogen) sup-
plemented with 10% fetal bovine serum (Gibco, Invitrogen) and 1%
penicillin/streptomycin solution (Gibco, Invitrogen) at 37 C and
5% CO2.
2.3.2. The chicken chorioallantoic membrane (CAM) assay
The anti-angiogenic and anti-neoplastic activity was assessed as
previously described, with slight modifications [8,54–56]. Briefly,
fertilized chicken eggs (n = 90–120, Pintobar, Portugal) were ini-
tially incubated horizontally at 37 C with 70% humidity for a
three-day period. Posteriorly, on the third day of development, in
a laminar-flow hood, eggs were cleaned by using 70% ethanol solu-
tion and a window, diameter around 2 cm, was made on the top of
the egg shells by thoroughly removing shell fragments, enabling
access to the CAM. The windows were then covered with invisible
tape (55  30 mm; BTK) to avoid egg dehydrating and incubated as
initially [54–56]. On the ninth day of development, four experi-
mental groups (n = 10) were tested: DMEM (Dulbecco’s modified
eagle medium as negative control), hydrogel, hydrogel_BVZ and
BVZ (Commercial anti-VEGF bevacizumab, Avastin, Genentech/
Roche, USA) as positive control. All experimental groups were trea-
ted at both 5.8 and 7.4 pH values. Pictures of the CAM implants
were taken over time in ovo by the use of a stereomicroscope
(Olympus S2  16) coupled to Cell B basic imaging software
(Olympus) to document vascular changes [57].
On the 17th day of development, samples of the CAM tissue
were excised using suture scissors, fixed with paraformaldehyde
solution 3.7% (v/v), processed, sectioned and stained. For quantifi-
cation purposes, the magnification of the stereomicroscope image
274 N.N. Ferreira et al. / European Journal of Pharmaceutics and Biopharmaceutics 119 (2017) 271–282was kept constant (7  ) and pictures taken ex ovo were processed
as 300  300 pixels around the hydrogel area. Blood vessels were
counted by the use of ImageJ 1.48v Software. Counts for each egg
were performed by two independent observers to minimize failure
and average values were used as a result.
To further analyze the anti-neoplastic activity, the eggs were
initially treated as previously described. On day 9 of development,
U251 cells (2  106 cells in 20 lL DMEM medium) were implanted
into the CAM using a matrigel support. After 3 days, tumor area
and perimeter was measured in ovo using the Cell B software
(Olympus) [8]. Eggs were than separated into two experimental
groups: hydrogel group (received 20 lL of hydrogel_BVZ pH 5.8)
and control group (received no treatment). On day 17 of develop-
ment, chorioallantoic membranes with tumors were excised, pho-
tographed for blood vessel quantification purposes and transferred
to histological cassettes embedded in paraffin for immunohisto-
chemistry analysis. Three independent CAM assays were
performed.2.3.3. Immunohistochemistry analysis
Representative 3 lm-thick of CAM sections containing microtu-
mors were used to immunohistochemical analysis, according to
the streptavidin–biotin peroxidase complex system (UltraVision
Large Volume Detection System anti-Polyvalent, HRP; LabVision
Corporation) [54,55].
Briefly, deparaffinised slides were rehydrated and submitted to
heat-induced antigen retrieval, 20 min at 98 C using 10 mM
citrate buffer (pH 6.0; Merck). After endogenous peroxidase inacti-
vation (3% v/v hydrogen peroxide solution) and washing in phos-
phate buffered saline (PBS), CAM sections were incubated with
the primary protein blocking solution followed by the primary
antibody raised against lectin (1:300, 2 hours- Vector Laboratories)
at room temperature. To complete the assay, sections were
sequentially washed with PBS and incubated with secondary anti-
body, streptavidin–biotin peroxidase complex followed by 3-
diaminobenzidine (DAB, Thermo Scientific), 10 min. Sections were
than counterstained with Gill-2 hematoxylin (Merck). Images of
the histological sections were acquired at 100  magnification
using an Olympus B  16 microscope connected to CellP image
processing software (Olympus).2.3.4. Statistical analysis
All experiments were performed in a blind manner, at least in
triplicate. For comparison of two independent groups at a certain
time point, the pair wise Student’s t-test was used for statistical
evaluation. In case of simultaneous comparison of all groups one-
way analysis of variance (ANOVA) with Tukey’s multiple compar-
ison tests was used, considering significant values to be 0.05
(p < 0.05).3. Results and discussion
The success of current anti-VEGF therapy applying beva-
cizumab, still presents some concerns, especially due to its
hydrophilicity, high molecular weight and low stability in biologic
fluids, which might be overcome by developing an efficient carrier
system for localized therapy. The purpose of the present study was
to develop a delivery system able to be applied by intratumoral
injections, allowing high drug concentrations at the tumor site,
improve drug stability and promote drug controlled release over
time. Alginate hydrogels were chosen for this propose since they
represent a biocompatible polyanion matrix able to interact with
the monoclonal antibody bevacizumab (isoelectric point ± 8.3),
especially at pH values lower than physiologic 7.4 [41], most likely,without altering drug structure, since their preparation does not
require the use of extreme temperatures or organic solvents.
3.1. Effect of pH and polyanion alginate on bevacizumab
conformational and thermal stability
The maintenance of protein biopharmaceutical conformational
stability is essential to assure biological activities [58]. To address
this issue, we have employed circular dichroism and intrinsic fluo-
rescence spectroscopy measurements to monitor secondary and
tertiary BVZ structure, respectively. Fig. 1A shows CD spectra of
BVZ, normalized for MRE, at pH 5.8 and 7.4 compared to BVZ in
the presence of different polymer proportions, for both pH values.
For all tested conditions, BVZ CD spectra exhibited structural ele-
ments related to b-sheet proteins, with a negative band between
210 and 220 nm [59]. The mixture of alginate polymer and BVZ
in the ratio 1:9 and 5:5 led to a small reduction of the CD signal
without spectra profile changes at both tested pH values. Further-
more, structure estimation did not indicate significant changes in
the secondary structure content of BVZ due to the presence of algi-
nate (see Table 1).
Fluorescence emission is an average of all contributions of tryp-
tophan residues present in the BVZ structure, which can undergo
slight changes according to the environment polarity caused by
pH modification [60]. Reinforcing the aforementioned results, the
BVZ structural stability in mixtures with alginate polymer (in
1:9, 5:5 and 9:1 ratios) was analyzed using intrinsic fluorescence.
Fig.1B shows the normalized BVZ fluorescence spectra at both pH
values, indicating no significant changes in BVZ tertiary structure.
Furthermore, analysis of kmax and < k > did not demonstrate differ-
ences between all samples.
DSC measurements provide heat changes during controlled
temperature modifications and might indicate the occurrence of
thermal denaturing events and disruptions of interactions that
maintain the tridimensional structure [61]. The DSC profiles of
BVZ and BVZ in the presence of alginate polymer, for both pH val-
ues, were similar to temperature-induced unfolding of a typical
humanized monoclonal antibody. Two transitions were observed.
The first event occurs around 70 C and is related to Fab (fragment
antigen binding) and one domain in Fc (fragment crystallizable)
unfolding fragment, while the second event corresponds to melting
of the Fc fragment, which occurs around 80 C, in agreement with
the previously reported BVZ profile [62]. Table 2 summarizes the
results of DSC measurements of BVZ and BVZ in the presence of
alginate for pH 5.8 and 7.4.
Values of melting temperature (Tm) and enthalpy appear to be
higher when BVZ is in the presence of the polymer. Although there
were no significant differences in the Tm between all samples, there
was a substantial increase in enthalpy when measures were con-
ducted in the presence of alginate. These data indicate that the
polyanion might improve protein thermal stability in both pH val-
ues by increasing the energy required for protein denaturation.
Furthermore, the presence of alginate may cause restricted protein
mobility, harming the unfolding process. The thermal stabilizing
nature action of polymers against protein has been mentioned in
several studies [63,64]. These hypotheses are supported by DC
and fluorescence analysis since the presence of the polymer did
not affect the secondary and tertiary protein structure. Altogether,
these results indicate that BVZ has structural and thermal stability
in the presence of the alginate polyanion for both tested
conditions.
3.2. Hydrogel preparation through electrostatic forces
Alginate, a natural polysaccharide derived from brown algae, is
composed by b-D-mannuronic acid residues (M blocks) and a-L-
Fig. 1. Spectroscopy analysis of BVZ and BVZ in the presence of different alginate proportions at pH 5.8 and 7.4. (A) Circular dichroism spectra were acquired in 50 mM
phosphate-acetate buffer and data were normalized for mean molar residual ellipicity. (B) Intrinsic fluorescence emmission spectra were obtained exciting the samples at
280 nm and collecting fluorescence emmission from 300 nm to 420 nm; data were normalized.
Table 1
Summary of spectroscopy results. Effect of pH value and polyanion alginate on BVZ conformational structure.
Technique Property BVZa Polymer:Protein
1:9 5:5 9:1
pH 5.8 pH 7.4 pH 5.8 pH 7.4 pH 5.8 pH 7.4 pH 5.8 pH 7.4
CDb a-helix 5 5 4 5 5 4 n/d
b-sheet 47 46 49 48 48 49
b-turn 17 17 17 17 17 16
Random coil 35 35 35 35 35 35
Fluorescencec kmáx (nm) 337 337 337 338 338 336 337 337
<k>(nm) 350.2 350.2 350.4 350.5 350.5 350.5 351.5 350.9
a Freshly prepared bevacizumab 0.3 mg.mL1.
b Secondary structure extracted by deconvolution of experimental CD spectra using CDNN deconvolution program. Results represent average of three determinations (%).
Standard deviation was lower than 5%.
c Wavelength of maximum emission (kmax) and mass spectral center (<k>) extracted from intrinsic fluorescence. Results represent average of three determinations.
Standard deviation was lower than 2.0 nm.
Table 2
Experimental values for melting temperatures and enthalpies of BVZ and BVZ in the presence of alginate polymer at pH 5.8 and 7.4.
Sample pH First transition Second transition
Tm (C)* Enthalpy* (Kcal/mol) Tm (C)* Enthalpy* (Kcal/mol)
BVZ 5.8 65.5 399.9 84 25.9
BVZ + Alginate 72.7 547.8 84.2 38.7
BVZ 7.4 69.6 334.9 82.9 27.2
BVZ + Alginate 72.2 546.9 84.2 40.04
* Data show an average of three measures. Standard deviations were less than 3 C and 10 Kcal/mol for temperature and enthalpy.
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blocks, arranged along the polymer chain. In the presence of diva-
lent ions, such as calcium, a crosslink between carboxylic groups
present on G blocks can provide the formation of a tridimensional
network [65–67]. The chemical crosslinking process used to pre-
pare hydrogels comprises a soluble salt, calcium chloride. External
gelation was chosen for hydrogel production once local variations
as temperature and pH are expected at the heterogeneous tumor
microenvironment. The control of stoichiometry between the poly-
mer and crosslinking agent, in addition to the use of co-injection
system between alginate and calcium chloride solutions, ensured
good homogeneity and stability of the produced polymeric
network.To evaluate the interaction between the oppositely charged BVZ
and alginate into the hydrogel system we have used zeta potential
measurements. ZP average values found for produced hydrogels
assumed values around 50.4 ± 2.7 mV at physiologic pH (7.4).
Introduction of BVZ protein promoted a decreased in ZP
(44.3 ± 3.2 mV), reinforcing an event of supramolecular associa-
tion between the anionic matrix and the positively charged pro-
tein. Furthermore, the ZP value of hydrogel_BVZ at pH 5.8 was
33.2 ± 1.11 mV. These results were significantly different
(p < 0.05) and highlight a stronger and enhanced interaction
between the protein and polyanion at pH 5.8. At this condition,
although the alginate hydrogel charge density does not appear to
change significantly between pH 7.4 and 5.8, according to their
pKa value, the pH drop promotes BVZ protonation and exhibition
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exposure of BVZ positive charges at pH 5.8 increases the protein-
polyanion association, promoting a reduction in the ZP value. Sch-
weizer and co-workers have previously explored electrostatic
interactions between calcium alginate hydrogel and a monoclonal
antibody (mAb) for its sustained release. The supramolecular
established interactions, demonstrated a pH dependence on the
release rates and stronger alginatemAb association under acidic
conditions, where the mAb carries a large number of positive
charges [41].
In summary, ZP data shows that BVZ loaded alginate hydrogel
self-assembly by electrostatic forces at both studied pH values.
However, the data also suggest stronger alginateBVZ interactions
at pH 5.8.
3.3. Hydrogel mechanical behavior
To enable an intratumoral application, the developed formula-
tions must be able to be delivered by a syringe through a needle.
As an injectable system, the formation of aggregates cannot be
allowed during the injection process, to avoid needle clogging.
Results of hydrogels, hydrogel_BVZ and commercial BVZ syringe-
ability are shown in Table 3. The observed syringeability values
were adequate for slow and continuous injections, with no evi-
dence for aggregate formation, ranging from 9 to 29 N.mm, within
the overall limit for manual injection [49]. Comparing the use of
two different crosslinking agent concentrations, higher concentra-
tion promotes a significant increase in the work required for
hydrogel ejection. Moreover, addition of BVZ also promoted a
higher seringeability value. Meanwhile, the absence of BVZ on
hydrogel formulation results in systems slightly more prone to
flow. A low syringeability value was expected for commercial
BVZ, which comprises an injectable solution for intravenous
administration. Values of work required for system seringeability
between 10 and 30 N were previously reported and classified as
injectable and suitable for local administration [68].
Syringeability results can predict a shear thinning behavior of
calcium alginate hydrogels. A decreased viscosity might be
observed due the increased shear rates. This condition leads to a
temporary network destruction against molecular alignment in
the flow direction. Therefore, the applied force promotes a reversi-
ble disruption or disorganization of supramolecular entities, allow-
ing flowability [49,69].
Rheological studies were designed to provide a detailed charac-
terization of hydrogel and hydrogel_BVZ flow behavior and its
mechanical structure. Representative plots from flow behavior
are displayed in Fig.2A. A typical non-Newtonian, shear thinning
behavior, was observed for all samples regardless of drug load or
pH value. The exhibited flow behavior, where decreased resistance
to flow is related to increased shear rates, is commonly described
for polymeric cross-linked alginate systems [70,71] and might be
favorable for the proposed application.
The absence of bevacizumab in the hydrogel system results in
an overlapping hydrogel profile for both 5.8 and 7.4 pH values.Table 3
Values of work required to expel each formulation from a syringe through a needle.
Formulations Concentration (mg/mL)
Polymer CaCl2
Hydrogel_5 27 5
Hydrogel_3 27 3
Hydrogel_BVZ 27 5
Bevacizumabb – –
a Values represents the mean (± standard deviation) of at least in six replicates at 25
b Commercial BVZ (Avastin 25 mg/mL).Moreover, addition of BVZ did not change the overall shape of
the flow curve, but resulted in an increase in the stress required
to generate an expressive deformation. These alterations might
occur by the establishment of supramolecular interactions, which
reduces chain mobility. However, it was expected that such behav-
ior would have a stronger mark at acidic environment. Interest-
ingly, hydrogel recovery did not occur immediately after shear
removal, since hysteresis area was remarkable for all rheograms.
When a shear stress is applied, the hydrogel network suffers partial
damage. If the structure rebuilds within a short period of time, the
structure experiences a shear thinning; otherwise, if restructuring
takes a long time, rheopexy is announced. Undergoing shear stress,
hydrogel_BVZ achieves structural reorganization connected to
increased viscosity. This profile might ensure adequate flow during
administration, followed by a tendency to thicken when stress is
removed. Such behavior indicates a promising matrix for injectable
drug delivery, performing a depot system following administration
[72].
Further rheological analysis was performed at the linear vis-
coelastic region, where sample can elastically strain and return
to its original state when straining is removed. A frequency sweep
(0.01 a 100 Hz) at constant stress (0.5 Pa) was performed to obtain
hydrogel and hydrogel_BVZ mechanical spectra. The variation of G0
and G’’ values as a function of frequency is shown in Fig. 2B. As
expected, all mechanical spectra revealed higher G0 than G00, con-
firming an elastic behavior predominance of hydrogels. Further-
more, storage and loss modulus exhibited a slight frequency
dependence. Increased G0 values were verified at lower pH condi-
tions. Under these conditions, alginate COO groups are proto-
nated, enhancing H-bonding and intermolecular cross-linking in
the hydrogel network leading a higher G0 values [73]. Rheological
parameters of the hydrogel tended to be higher than hydro-
gel_BVZ. These results showed that addition of BVZ displayed
internal network weakness what might be attributed to the drug
plasticizer effect.
The use of power law model, G0=S.xn, where S is the gel
strength, x is the angular frequency and n the viscoelastic expo-
nent, provides parameters that represent hydrogel’s structure
and strength. When hydrogel system exhibits a high crosslink den-
sity, the structure is considered strong and S values are high. More-
over, n value trends to decrease [53,74]. Thus, the evaluation of
modified S and n values may enhance the occurrence of structural
changes. S and n values for hydrogel and hydrogel_BVZ at pH 5.8
and 7.4 are listed in Table 4. A significant difference in S values
was observed when the pH changes from 7.4 to 5.8. These findings
might indicate an adoption of differential structure with higher
rigidity due to the acidic environment.
Oscillatory studies showed that the drop in pH might lead to
systems with higher structural organization once in the presence
of lactic acid (pH 5.8); a significant increase in G0 e G00 values
(Fig. 2B) was verified in addition to higher S values (Table 4).
Increased elasticity at acidic environment occurs due to accentu-
ated positively charged protein availability to ensure supramolec-
ular interactions with alginate matrix [41]. Thus, hydrogel_BVZWork (N.mm)a
Bevacizumab
– 24 ± 2.1
– 21 ± 0.8
3 29 ± 1.1
25 9 ± 0.3
C.
Fig. 2. Rheological studies of hydrogel and hydrogel_BVZ, pH values 5.8 and 7.4. (A) Flow rheograms highlighting a shear thinning behavior. (B) Mechanical spectra: storage
modulus G0 (empty symbol) and loss modulus G00 (full symbol) as a function of frequency. Results represent average of three determinations. Standard deviation were less
than 10% and have been omitted for clarity. Data were collected at 25 ± 0.5 C.
Table 4
Viscoelastic exponent (n) and gel strength (S) of hydrogel and hydrogel_BVZ at pH 7.4
and 5.8.
Sample n* S*
Hydrogel 7.4 0.12 ± 0.01 66.20 ± 5.1
Hydrogel_BVZ 7.4 0.13 ± 0.08 34.01 ± 2.4
Hydrogel 5.8 0.11 ± 0.02 110.81 ± 3.1
Hydrogel_BVZ 5.8 0.21 ± 0.03 53 ± 2.0
* Value represents the mean (±SD) of three replicates.
N.N. Ferreira et al. / European Journal of Pharmaceutics and Biopharmaceutics 119 (2017) 271–282 277may adopt a different structural organization according to pH what
might provide a differential BVZ release profile at the acidic tumor
microenvironment where the system should be applied as local
therapy.Fig. 3. Sorption profile (S%) of hydrogel and hydrogel_BVZ in phosphate-acetate
buffer pH 5.8 and 7.4. Swelling behavior during three hours of monitoring. Results
represents average of three determinations. Statistical significance between exper-
imental groups were found after 2.5 h (p > 0.05).3.4. Hydrogel liquid uptake properties
Polymeric matrices have received considerable attention over
the past few years to develop improved drug delivery systems
for protein drugs. From these systems, release of active drugs is
dependent of drug diffusion through hydrogel matrix channels
and pores, disruption of supramolecular interactions established
between the matrix and drug and, subsequently, linked to polymer
degradation [4]. Once these processes are directly related to liquid
diffusion into the polymer network, the swelling behavior of the
polymeric systems is an important property to be investigated
and might promote a notable influence on drug-controlled release
over time [75]. However, it is well established that the crosslinking
process can promote immobilization of polymer chains, and conse-
quently, reduction of the swelling ability [76]. The sorption profiles
(S%) of hydrogel and hydrogel_BVZ in phosphate-acetate buffer at
pH 5.8 and 7.4, along three hours, are shown in Fig. 3.
Results revealed that hydrogel and hydrogel_BVZ exhibited
high liquid uptake ability for both pH 5.8 and 7.4. Moreover, these
systems appear to present pH sensitive liquid uptake behavior
once after 2.5 h, a significant differences in the sorption volume
(p > 0.05) between hydrogel at pH 5.8 and 7.4 was observed. A
decreased uptake capacity at pH 5.8 in anionic polymer hydrogels
is related to hydrogen bound formation between the –COOH and –
OH groups [77]. Liquid uptake ability was reduced by the presence
of BVZ (see hydrogel_BVZ). This reduction might be attributed tothe electrostatic interactions between the protein and anionic
matrix, resulting in decreased charge density and repulsive forces
into the network and, consequently, an approximation between
the chains, obstructing the liquid absorption process. These results
are in agreement with the zeta potential measurements, which
have emphasized stronger interactions at lower pH values.
Due to the expected pH decrease in tumor microenvironment,
these results might evidence important features acquired by the
hydrogel system according to pH changes.3.5. Hydrogel surface morphology
Surface morphology of hydrogel and hydrogel_BVZ was
observed by SEM studies and the results are shown in Fig. 4. SEM
photographs of hydrogels (  300) revealed a rough surface highly
interconnected by calcium ion cross-linked, yielding the formation
of irregular pores with variable size, ranging from 100 nm to
100 lm, which may provide important features to this system.
As a general aspect, calcium alginate hydrogels showed a squa-
mous sheet on the surface, similar to those previously described
Fig. 4. SEM photomicrographs of freeze-dried hydrogel and hydrogel_BVZ carried out at high magnification (300  ) and 37 C. (A) Hydrogel at physiology condition (pH 7.4).
(B) Hydrogel at acidic environment (pH 5.8). (C) Hydrogel_BVZ at physiological condition (pH 7.4). (D) Hydrogel_BVZ at acidic environment (pH 5.8).
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sent any alteration on surface morphology due to pH modifica-
tions. However, the analysis of Fig. 4C and D demonstrate that
hydrogel_BVZ originating a less squamous aspect at acidic environ-
ment, with a notable decrease in pore density. This observation can
indicate that the association between protein-polyanion, at this
condition, promotes a network reorganization, which adopts a dif-
ferent structure, corroborating all the data described above. The
developed hydrogel_BVZ systems behave as supramolecular enti-
ties responsive to external stimuli as pH drop verified in the tumor
microregion. The question is, therefore, the evaluation of system
performance on tumoral environment.3.6. Investigation of the anti-angiogenic activity by chick embryo
chorioallantoic membrane assay
The purpose of use drug delivery systems to optimize the ther-
apeutic effect in pathological processes such as cancer is promis-
ing; however, the understanding of system behavior towards
biological environments is extremely important [79].
The increasing interest of the chick embryo as a model in bio-
logical and pharmaceutical research is based on the fact that the
CAM offers an advantage to be a simple model, feasible for numer-
ous samples in addition to its reliability [57,80]. The potential use
of the CAM to study in vivo new vessel formation or their inhibition
has been outlined by a series of publications, mainly, due to its
dense capillary network [54,81–84]. Furthermore, this model is
also noteworthy for the evaluation of drug delivery system (DDS)
performance [85].
The ability of calcium alginate hydrogels to release anti-
angiogenic factors was evaluated by the CAM assay. Different sam-
ples (pH 7.4 and 5.8) were applied on the CAM on day 9 of embry-
onic development [86,87]. Stereomicroscopy images from DMEM,
hydrogel, hydrogel_BVZ and BVZ groups (pH 7.4 and 5.8) acquired
in ovo, after 3 days of treatment, are shown in Fig. 5A. It is possible
to observe that the DMEM group has a typical vasculature regard-
less of the pH values. However, the hydrogel_BVZ group, after three
days of treatment, exhibited collapsed blood vessels around the
area where the systems were implanted (Fig. 5A). These results
were also observed, although to a lesser degree, when BVZ was
applied (Fig. 5A).
Although collapsed blood vessels can be found upon BVZ treat-
ment, the dimension of its anti-angiogenic activity was less
remarkable comparing to BVZ loaded hydrogel activity (Fig. 5A).
Fewer blood vessels could be seen in the hydrogel_BVZ group,
whereas the group treated with BVZ continued to show a dense
capillary network. It can also be observed that the peripheral ves-
sels grew centrifugally, avoiding the hydrogel_BVZ area, with an
overall decrease in vascular density (Fig. 5A).Macroscopic evaluation of anti-angiogenic response was carried
out semi-quantitatively using ex ovo processed images after 7 days
of applied treatment (Fig. 5B). Vessel counting disclose significant
differences, converging between experimental groups. As
expected, our negative control (DMEM) exhibited normal blood
vessel growth and the number of vessels was higher than all other
experimental groups, especially at pH 7.4. It can also be noticed
that although blood vessels were able to proliferate in the presence
of hydrogels, the average score of replicates showed that hydrogels
by themselves, appear to promote reduction in blood vessel forma-
tion. The developed hydrogel provided modifications in the vessel
grow pattern in addition to might act as an adsorbent of important
key factors involved in vessel formation, a property strongly
related to their sorption capacity. However, no difference between
hydrogel and BVZ group was found at pH 5.8. Although BVZ
applied to the CAM has resulted on the visualization of collapsed
blood vessels, blood vessels seem to recover after a few days.
Our greatest promise is based on the fact that hydrogel_BVZ
could promote further reduction in vascular density compared to
BVZ alone (commercial anti-VEGF drug), results demonstrated at
both pH values. These data, together with physicochemical charac-
terization, complies with the hypothesis that our hydrogels might
promote improvements on drug stability and activity. Despite both
pH values exhibiting the same profile, statistically, it was not pos-
sible to correlate system activity and pH by using the CAM assay.
These, jointly with other published data, leads us to believe that
the CAM model, displaying a physiological pH, might have worked
as a buffer [80,85,88,89].
The observation of groups treated with hydrogel_BVZ has fur-
ther shown that the vascular apparatus becomes less dense over
time (Fig. 6). This fact can indicated that developed hydrogel might
promote BVZ controlled release over time. Besides reducing costs,
extended half-life by slowing the release of antibody drugs can
improve treatment effectiveness [18]. It has been demonstrated
that BVZ can be released from polymeric systems over an extended
period. Andrew and co-workers showed nanostructured meso-
porous silica films, anionic materials similar to alginate hydrogels,
which could interact with bevacizumab by supramolecular interac-
tions, promoting sustained release of BVZ over a period
of > 30 days when it was applied on simulated eye vitreous [2].
Poly(DL-lactide-co-glycolide), known as PLGA nanoparticles, could
release BVZ in a sustained fashion for over 90 days [19]. A devel-
oped thermosensitive biodegradable and biocompatible hydrogel
produced by poly(2-ethyl-2-oxazoline)-b-poly(e-caprolactone)-b-
poly(2-ethyl-2-oxazoline) (PEOz-PCL-PEOz) was able to release
BVZ at a constant rate of 40 lg/day for 11 days without burst effect
on its initial state [18].
These results highlighted that alginate hydrogel might promote
drug-sustained release over time and displays improved anti-
Fig. 5. (A) Typical stereomicroscopy images acquired in ovo after 3 days of applied treatment. Experimental groups DMEM, hydrogel, hydrogel_BVZ and BVZ were analyzed at
pH 7.4 and 5.8. (B) Ex ovo quantification of macroscopic blood vessels (pH 7.4 and 5.8) after 7 days of applied treatment. Results are expressed as mean SD; n = 10. One-way
analysis of varience followed by tukey’s multiple comparison were used for statistical analysis (p < 0.0.5). Difference p < 0.05 were considered statistically significant (**).
Fig. 6. Stereomicroscopy images acquired in ovo show vascular changes over the experimental procedure. Groups treated with hydrogel_BVZ and BVZ at pH 7.4.
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drug for both studied pH values, which include extreme conditions
encountered at the tumor environment.3.7. Analysis of tumor development and progression treated by
hydrogel_ BVZ
Implantation of U251 tumor cells (2  106 cells in 20 mL DMEM
medium) was performed to create a microtumor that would allow
the analysis of system anti-angiogenic activity together with tumor
development and progression by measuring tumor area and
perimeter. Fig. 7A show pictures taken ex ovo for eggs treated with
hydrogel_BVZ and eggs that received no treatment after 5 days of
applied therapy. It can be noticed that the anti-angiogenic therapy
induced blood vessel disorganization and inhibition of the
ingrowth of new vessels, promoting a significant reduction in vas-
cular density (Fig.7A).
Results of blood vessel counts after CAM excision (Fig.7B)
showed a tendency for blood vessels reduction ( ± 30%) when the
anti-angiogenic treatment (hydrogel_BVZ) was applied. Fig. 7C
depicts the tumor areas and perimeters at two different moments:
day 1 represents tumor dimensions before treatment and day 5
relates to tumor measurements 4 days post anti-angiogenic ther-
apy. As control, a group of eggs did not receive any treatment. In
general, there was a propensity to a decrease in tumor size when
hydrogel_BVZ were applied. Anti-VEGF treatment appears to pro-
mote tumor reduction in about 50% compared to the untreated
group. However, further investigation remains required to support
these results.
Immunohistochemistry evaluation of histological samples,
especially the microscopic identification of blood vessels, provides
valuable and useful qualitative and quantitative information to
study angiogenesis [54]. Histological analysis was performed on
microtumor sections. Chick blood vessels were labeled with
biotinylated Sambucus Nigra lectin (SNL-lectin) to highlight
regions containing blood vessels. Light microscopy photographs
of the immunohistochemical staining from excised CAM contain-Fig. 7. Inhibition of tumor growth and angiogenesis by alginate hydrogel loaded with B
after 5 days of treatment/immunohistochemical staining from excised CAM containing m
quantification of macroscopic blood vessel. (C) Area (cm2) and perimeter (cm) of tumors
anti-angiogenic treatment; day 5 relates to tumor measurements 4 days post anti-angiog
as mean SD; n = 3. One-way analysis of varience followed by Tukey’s multiple comparing microtumors (Fig.7A) indicates that the control group pos-
sesses a higher number of microscopic blood vessels compared to
experimental groups that received hydrogel_BVZ treatment. Fur-
thermore, the control group appears to have high degree of blood
vessel organization.
Taken together, the CAM model provides valuable insights into
physiological and histological vascular system responses to applied
therapy. Moreover, in vivo data strongly suggest that BVZ loaded
hydrogels have increased anti-angiogenic activity and might dis-
play anti-neoplastic effects in extreme pH values encountered for
solid tumors.
4. Conclusions
The use of drug delivery platforms to optimize therapeutic
effect in pathological processes such as cancer is undoubtedly
promising and should be specifically designed considering patho-
logic features. This concept provides adjustment between effects
and interactions including several research areas to accomplish
material self-assembly and stimulation of spontaneous processes.
In this paper, we successfully designed an innovative protein
loaded hydrogel delivery system for localized anti-VEGF cancer
therapy. This system would allow local application in a minimally
invasive manner, refilling the formation of drug depots for slow
and continuous protein release to the tumor and surrounding tis-
sues, in addition to provide drug stability, especially in acid envi-
ronments. The CAM assay demonstrated that BVZ has
pronounced anti-angiogenic activity when loaded into hydrogel
independently of pH (5.8 and 7.4). Furthermore, this system might
provide an anti-neoplastic effect. Since these studied values repre-
sent extreme conditions encountered in the tumor environment,
we anticipated that the developed systems have potential to be
applied in a variety of solid tumors.
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